CONTEXT: Report of two abstracts presented by Lucence at ASCO 2021 detailing their molecular profiling of advanced cancers in a real-world setting using a liquid biopsy assay and results of targeted sequencing analysis in NSCLC from an Asian population. In addition Lucence announced the formation of a their medical advisory board in the US.
IMPACT: low
READ TIME: 3 mins
Quality Level Mean [1 – 10]: 7
1. “Lucence will be sharing two abstracts as part of Virtual 2021 ASCO highlighting the use of its ultrasensitive amplicon-based next-generation sequencing (NGS) assay, LiquidHALLMARK®, for advanced cancers in real-world settings.”
2. “Gilberto Lopes, MD, MBA, Interim Chief of Medical Oncology at the Sylvester Comprehensive Cancer Center will join as advisor. As part of the 2021 ASCO Annual Meeting, precision oncology company Lucence is sharing real-world data supporting clinical applications of its amplicon-based liquid biopsy assay.”
3. “Gilberto de Lima Lopes Jr., MD, MBA, FAMS is Interim Chief for the Division of Medical Oncology, Medical Director for International Programs and Associate Director for Global Oncology at the Sylvester Comprehensive Cancer Center, and Professor of Clinical Medicine at the Miller School of Medicine at University of Miami.”
4. “Story continues. The first abstract (#3062), authored by Jonathan Poh and contributors, Comprehensive molecular profiling of advanced cancers in a real-world setting using an ultrasensitive amplicon-based next-generation sequencing (NGS) liquid biopsy assay, detected ctDNA in 70% of cancer samples.”
5. “As a follow up to Lucence’s programming for 2021 ASCO, on June 29, 2021 at 8:30 PM EDT, Lucence will host New Frontiers in Liquid Biopsy for Lung Cancer, a webinar covering current and cutting-edge applications of liquid biopsy in thoracic oncology.”
Source URL: https://finance.yahoo.com/news/lucence-presents-real-world-evidence-130000234.html